Your browser does not support JavaScript!
 

 

:::
首頁 > 研究單位 > 中醫藥基礎研究組
翁芸芳(Ueng, Yune-Fang)

翁芸芳個人生活照姓名:翁芸芳 (Ueng, Yune-Fang)
職稱:研究員兼中醫藥基礎研究組組長
電話:2820-19996351、6361
E-mailueng@nricm.edu.tw 

 

學歷:
國立台灣大學醫學院生物化學研究所 博士 

主要經歷:
國立台灣大學醫學院毒理學研究所 博士後副研究員
美國范德堡大學醫學院生化所暨分子毒理中心 博士後研究員

其他經歷:
台灣毒物學會幹事 
台灣藥理學會藥理簡訊編輯委員 
台灣毒物學會會員 
台灣藥理學會會員

學術榮譽事項:
中華民國斐陶斐榮譽學會 
毒藥物防治學術獎座

專長:
生化學,藥學,毒理學

研究簡介:
      藥物代謝酶在外來物包括天然物、藥物、環境污染物之生物活性及解毒作用中扮演重要角色。
研究主題在
(一)、探討天然物與藥物代謝酶之相互影響以評估產生藥物交互作用之可能性;
(二)、確認天然物之代謝產物並了解參與其代謝之人類藥物代謝酶。

期刊論文:

      NCBI PubMed :  Yune-Fang Ueng (Please click!!)

  1. Ueng, Y.-F.*, Lu, C.-K., Yang, S.-H., Wang, H.-J., and Huang C.-C., Potentiation of the anticoagulation effect of warfarin by the herbal remedy Shu-Jing-Hwo-Shiee-Tang in rats: the dosing regimen and pharmacokinetic interaction. Drug Metab. Pharmacokinet., in press, 2016, Dec.
  2. Wang, S.-F., Chen, M.-S., Chou, Y.-C., Ueng, Y.-F., Yin, P.-H., Yeh, T.-S., Lee, H.-C.*, Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway. Oncotarget, 2016, Sep., 7(45), 74132-74151.
  3. Chang, Y.-P., Huang, C.-C., Shen, C.-C., Tsai, K.-C., and Ueng, Y.-F.*, Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites. Drug Metab. Pharmacokinet., 30, 374-383, 2015, Dec.
  4. Lin, L.-W., Ueng, Y.-F., Tsai, K.-C., Hsu, H.-J., Shih, C.-C., and Chen, W.-C.*, Investigation of Interaction between Shu-Gin-Hwai-Shen-tang and Anticoagulant Warfarin from the Perspective of Structural Biology., Taiwan Journal of Chinese Medicine (臺灣中醫醫學雜誌), 13(1), 1-12, 2015.
  5. Ueng, Y.-F.*, Chen, C.-C., Huang, Y.-L., Lee, I-J., Yun, C.-H., Chen, Y.-H., and Huang, C.-C., Effects of aqueous extract of Ruta graveolens and its ingredients on cytochrome P450, uridine diphosphate (UDP)-glucuronosyltransferase, and reduced nicotinamide adenine dinucleotide (phosphate) (NAD(P)H)-quinone oxidoreductase in mice. J. Food Drug Anal., 23, 516-528, 2015. Aug.
  6. Lo, S.-N., Shen, C.-C., Chang, C.-Y., Tsai, K.-C., Huang, C.-C., Wu, T.-S., and Ueng, Y.-F.*, The effect of oxidation on berberine-mediated CYP1 inhibition: oxidation behavior and metabolite-mediated inhibition. Drug Metab. Dispos., 43, 1100-1107, 2015, July.
  7. Lee, K.-H.a, Ueng, Y.-F.a, Wu, C.-W., Chou, Y.-C., Ng, Y.-Y.*, Yang, W.-C., The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in hemodialysis patients – case reports and literature reviews. J. Clin. Pharm. Therapeut. doi: 10.1111/jcpt.12239, 2014.
  8. Lo, S.-N., Chang, Y.-P., Tsai, K.-C., Chang, C.-Y., Wu, T.-S.**, and Ueng, Y.-F.*, Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling. Toxicol. Appl. Pharmacol., 272, 671-680, 2013. Nov.
  9. Wang, S.-F., Chou, Y.-C., Mazumder, N., Kao, F.-J., Nagy L. D., Guengerich, F. P., Huang, C., Lee, H.-C., Lai, P.-S., and Ueng, Y.-F.*, 7-Ketocholesterol induces P-glycoprotein through PI3K/mTOR signaling in hepatoma cells. Biochem. Pharmacol., 86,548-560, 2013, Aug.
  10. Chou, Y.-C., Wang, Y.-K., Charng, M.-J., and Ueng, Y.-F.*, Determination of serum atorvastatin concentrations in lipid-controlling patients with and without myalgia syndrome. J. Food Drug Anal. 21,147-153, 2013, Jun.
  11. Ueng, Y.-F.*, Chen, C.-C., Yamazaki, H., Kiyotani, K., Chang, Y.-P., Lo, W.-S., Li, D.-T., and Tsai, P.-L., Mechanism-based inhibition of CYP1A1 and CYP3A4 by the furanocoumarin chalepensin. Drug Metab. Pharmacokinet. 28, 229-238, 2013, Jun.
  12. Lo W.-S., Lim Y.-P., Chen, C.-C., Hsu, C.-C., Souček, P., Yun, C.-H., Xie, W., and Ueng Y.-F.*, A dual function of the furanocoumarin chalepensin in inhibiting Cyp2a and inducing Cyp2b in mice: the protein stabilization and receptor-mediated activation. Arch. Toxicol., 86, 1927-1938, 2012, Dec.
  13. Souček, P., Kondrová, E., Heřmánek, J., Stopka, P., Boumendjel, A., Ueng, Y.-F., & Gut, I. (2011). New model system for testing effects of flavonoids on doxorubicin-related formation of hydroxyl radicals. Anti-cancer Drugs, 22(2),  176-184. doi:10.1097/CAD.0b013e328341a17b
  14. Ueng, Y.-F., Chen, C.-C., Chung, Y.-T., Liu, T.-Y., Chang, Y.-P., Lo, W.-S., . . . Li, D.-T. (2011). Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. British Journal of Pharmacology, 163(6), 1250-1262. doi:10.1111/j.1476-5381.2011.01341.x
  15. Ueng, Y.-F., & Lin, Y.-L. (2011). Effects of ginsenoside Rd and Panax ginseng extract on Cyp1a, Cyp2b, Cyp2c, Cyp2e1, and Cyp3a activities in C57BL/6JNarl mice. Journal of Chinese Medicine, 22(3-4), 143-152.
  16. Ueng, Y.F* Tsai, C.C., Lo, W.S., Yun, C.H. (2010) Induction of hepatic cytochrome P450s by the herbal medicine,Sophora  flavescens extract in rats: the impact on the elimination of theophylline. Drug Metab. Pharmacokinet.,25:560–567.
  17. Chou, Y.C., Lin, M.H., Chung, Y.T., Liu, T.Y., Wang, S.Y., Chau, G.Y., Chi, C.W., Lee,C.H., Souček, P.,Krausz, K., Gelboin, H.V., and Ueng, Y.F.* (2010) The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes. J. Pharm. Sci., 99, 1063-1077.
  18. Ueng, Y.F.*, Chen, C.C., and Tsai, C.C. (2009) Differential inductive profiles of  hepatic cytochrome P450s by the extracts of Sophora flavescens in male and female C57BL/6JNarl mice. J. Ethnopharmacol., 126,437-446.
  19. Pan, W.C., Chen, R.M., Shen, Y.C., Chen, C.C., and Ueng, Y.F.* (2009) Suppressive effect of tobacco smoke extracts on oral P-glycoprotein function and its impact in smoke-induced insult to oral epidermal cells.Toxicol. Lett., 185, 116-123.
  20. Wu G.J., Chen T.L., Ueng Y.F., and Chen R.M.* (2008) Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharidestimulated macrophages through suppression of toll-like receptor 4-mediated c-Jun N-terminal kinase phosphorylation and activator protein-1 activation. Toxicol Appl Pharmacol., 228, 105-113.
  21. Lee H.L., Chang L.w., Wu J.P., Ueng Y.F.,Tsai M.H., Hsieh D.P.H., and Lin P.* (2008)
    Enhancements of 4-(methylnitrosamino)-1-(3-pyridy1)-1-butanone(NNK) metabolism and carcinogenic risk via NNK/Arsenic interaction.Toxicol. Appl. Pharmacol., 227, 108-114
  22. Su C.R., Ueng Y.F., Dung N.X., Reddy V.B., and Wu T.S. (2007) Cytochrome P450 3A4 inhibitors and other constituents of Fibraurea tinctoria. J. Nat. Prod., 70, 1930-1933.
  23. Ueng Y.F.*, Jan W.C., Don M.J., Ho L.K., and Chen C.F. (2006) Oxidative metabolism of the alkaloid rutaecarpine by human cytochrome P450s. Drug Metab. Dispos., 34, 821-827.
  24. Jan W.C., Don M.J., Chen C.F., Ho L.K., and Ueng Y.F.* (2006) Characterization of mouse cytochrome P450-catalyzed oxidative metabolism of rutaecarpine, an alkaloid of the herbal medicine Evodia rutaecarpa. J. Food Drug Anal., 14, 159-165.
  25. Kuo Y.H., Lin Y.L., Don M.j., Chen R.M., and Ueng Y.F.*(2006) Induction of cytochrome P450-dependent monooxygenase by extracts of the medicinal herb Salvia miltiorrhiza. J. Pharm. Pharmacol., 58, 521-527
  26. Ueng Y.F.*, Yu H.J., Lee C.H., Peng C., Jan W.C., Ho L.K., Chen C.F., and Don M.J.* (2005) Identification of the microsomal oxidation metabolites of rutaecarpine, a main active alkaloid of the medicinal herb Evodia rutaecarpa. J. Chromatogr. A, 1076, 103-109
  27. Ueng Y.F.*, Chieh C.H., and Don M.J. (2005) Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole. Food Chem. Toxicol., 43, 707-712.
  28. Chou Y.C., Ueng Y.F.*, Chou C.Y., and Tien J.H. (2005) Dimemorfan N-demethylation by mouse liver microsomal cytochrome P450 enzymes. Life Sci., 77, 735-745.
  29. Ueng Y.F.*, Tsai T.H., Don M.J., Chen R.M., and Chen T.L. (2005) Alteration of the pharmacokinetics of theophylline by rutaecarpine, an alkaloid of the medicinal herb Evodia rutaecarpa. J. Pharm. Pharmacol., 57, 227-232.
瀏覽數